FENOFIBRATE | A075753 | RHODES PHARMACEUTICALS LP
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from EAS Consulting Group (Jubilant Generics) FDA-2017-P-4245 · 4 docket documents Jubilant Generics Ltd., represented by EAS Consulting Group, filed this citizen petition on July 13, 2017, requesting that the FDA amend the Orange Book to designate "Reference Standard" (RS) status to a fenofibrate capsule product currently available in the market in strengths of 67 mg, 134 mg, and | 505(q) | 2017-07-14 | Withdrawn | EAS Consulting Group (Jubilant Generics) |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.1767
per ea
Lowest NADAC/Unit
$0.0885
per ea
Brand NDCs
0
Generic NDCs
3
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 42858020001FENOFIBRATE 200 MG CAPSULE | $0.1767 | EA | Generic | — | 2026-06-17 |
| 42858013401FENOFIBRATE 134 MG CAPSULE | $0.1141 | EA | Generic | — | 2026-06-17 |
| 42858006701FENOFIBRATE 67 MG CAPSULE | $0.0885 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.